Mozart Therapeutics makes its official debut, jumping into the hot Treg R&D field with some big-name investors backing it

Treg cells have been getting more and more attention recently among autoimmune specialists. There’s been Jeff Bluestone’s Sonoma, the $157 million launch of GentiBio this summer and Egle Therapeutics — which launched just last week — to name a few.

Now, there’s a new Treg player jumping in...

Click to view original post